197 related articles for article (PubMed ID: 28696229)
1. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
[TBL] [Abstract][Full Text] [Related]
2. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
3. Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine.
Ceckova M; Reznicek J; Ptackova Z; Cerveny L; Müller F; Kacerovsky M; Fromm MF; Glazier JD; Staud F
Antimicrob Agents Chemother; 2016 Sep; 60(9):5563-72. PubMed ID: 27401571
[TBL] [Abstract][Full Text] [Related]
4. Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
Colclough N; Alluri RV; Tucker JW; Gozalpour E; Li D; Du H; Li W; Harlfinger S; O'Neill DJ; Sproat GG; Chen K; Yan Y; McGinnity DF
Drug Metab Dispos; 2024 Jan; 52(2):95-105. PubMed ID: 38071533
[TBL] [Abstract][Full Text] [Related]
5. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
6. Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate).
Ceckova M; Reznicek J; Deutsch B; Fromm MF; Staud F
PLoS One; 2018; 13(8):e0202706. PubMed ID: 30114293
[TBL] [Abstract][Full Text] [Related]
7. Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions.
Boonnop R; Meetam P; Siangjong L; Tuchinda P; Thongphasuk P; Soodvilai S; Soodvilai S
Drug Metab Pharmacokinet; 2023 Jun; 50():100500. PubMed ID: 36948091
[TBL] [Abstract][Full Text] [Related]
8. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
Sato S; Tohyama K; Kosugi Y
Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
[TBL] [Abstract][Full Text] [Related]
9. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1.
Wegler C; Gazit M; Issa K; Subramaniam S; Artursson P; Karlgren M
J Pharm Sci; 2021 Jan; 110(1):388-396. PubMed ID: 33007277
[TBL] [Abstract][Full Text] [Related]
11. Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.
Feng B; West M; Patel NC; Wager T; Hou X; Johnson J; Tremaine L; Liras J
J Pharm Sci; 2019 Jul; 108(7):2476-2483. PubMed ID: 30794795
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
Mukkavilli R; Jadhav G; Vangala S
Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
[TBL] [Abstract][Full Text] [Related]
13. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
[TBL] [Abstract][Full Text] [Related]
14. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Jacqueroux E; Mercier C; Margelidon-Cozzolino V; Hodin S; Bertoletti L; Delavenne X
Fundam Clin Pharmacol; 2020 Feb; 34(1):109-119. PubMed ID: 31411766
[TBL] [Abstract][Full Text] [Related]
15. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
16. Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates.
Mandíková J; Volková M; Pávek P; Česnek M; Janeba Z; Kubíček V; Trejtnar F
Toxicology; 2013 Sep; 311(3):135-46. PubMed ID: 23856525
[TBL] [Abstract][Full Text] [Related]
17. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.
Pan G; Giri N; Elmquist WF
Drug Metab Dispos; 2007 Jul; 35(7):1165-73. PubMed ID: 17437964
[TBL] [Abstract][Full Text] [Related]
18. Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro.
Moss DM; Liptrott NJ; Curley P; Siccardi M; Back DJ; Owen A
Antimicrob Agents Chemother; 2013 Nov; 57(11):5612-8. PubMed ID: 24002095
[TBL] [Abstract][Full Text] [Related]
19. Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier.
Li Y; Wu Q; Li C; Liu L; Du K; Shen J; Wu Y; Zhao X; Zhao M; Bao L; Gao J; Keep RF; Xiang J
PLoS One; 2016; 11(6):e0157576. PubMed ID: 27300692
[TBL] [Abstract][Full Text] [Related]
20. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
